Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 1, 2011, Pages 195-201

  Proust Lima, Cécile ^a,b   Taylor, Jeremy M G ^c   Sécher, Solne ^a,b   Sandler, Howard ^d   Kestin, Larry ^e   Pickles, Tom ^f   Bae, Kyoungwha ^g   Allison, Roger ^h   Williams, Scott ⁱ  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF MICHIGAN   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g RADIATION THERAPY ONCOLOGY GROUP   (United States)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

; Progression of disease; Prostate cancer; Prostate specific antigen; Radiation therapy; Radiosensitivity

Indexed keywords

PROGRESSION OF DISEASE; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION THERAPY; RADIOSENSITIVITY;

ANTIGENS; DISEASE CONTROL; DISEASES; RADIATION;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RECURRENCE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE FRACTIONATION;

AGED; COHORT STUDIES; DOSE FRACTIONATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; STATISTICS, NONPARAMETRIC;

EID: 78649982102     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.10.008     Document Type: Article

References (30)

1. G.M. Duchesne, and L.J. Peters What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 44 1999 747 748
2. J.F. Fowler, M.A. Ritter, and R.J. Chappell What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56 2003 1093 1104
3. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101
4. A. Dasu Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 19 2007 289 301
5. D.J. Brenner, A.A. Martinez, and G.K. Edmundson Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
6. J. Fowler, R. Chappell, and M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
7. S.G. Williams, J.M. Taylor, and N. Liu Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer Int J Radiat Oncol Biol Phys 68 2007 24 33
8. D.J. Demanes, R.R. Rodriguez, and G.A. Altieri High dose rate prostate brachytherapy: The California Endocurietherapy (CET) method Radiother Oncol 57 2000 289 296
9. P.A. Kupelian, D.S. Mohan, and J. Lyons Higher than standard radiation doses (> or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer Int J Radiat Oncol Biol Phys 46 2000 567 574
10. A.A. Martinez, L.L. Kestin, and J.S. Stromberg Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: The William Beaumont phase II dose-escalating trial Int J Radiat Oncol Biol Phys 47 2000 343 352
11. J.Z. Wang, M. Guerrero, and X.A. Li How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55 2003 194 203
12. D.J. Brenner Hypofractionation for prostate cancer radiotherapy - What are the issues? Int J Radiat Oncol Biol Phys 57 2003 912 914
13. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
14. S.M. Bentzen, and M.A. Ritter The alpha/beta ratio for prostate cancer: What is it, really? Radiother Oncol 76 2005 1 3
15. C. Proust-Lima, J.M. Taylor, and S.G. Williams Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts Int J Radiat Oncol Biol Phys 72 2008 782 791
16. J.M. Taylor, M. Yu, and H.M. Sandler Individualized predictions of disease progression following radiation therapy for prostate cancer J Clin Oncol 23 2005 816 825
17. M. Roach, K. Winter, and J.M. Michalski Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study Int J Radiat Oncol Biol Phys 60 2004 1351 1356
18. S.G. Williams, G.M. Duchesne, and N.K. Gogna An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk Int J Radiat Oncol Biol Phys 65 2006 351 357
19. L.L. Kestin, F.A. Vicini, and E.L. Ziaja Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy Cancer 86 1999 1557 1566
20. S.G. Williams, G.M. Duchesne, and J.L. Millar Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 60 2004 1082 1087
21. T. Pickles, C. Kim-Sing, and W.J. Morris Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias Int J Radiat Oncol Biol Phys 57 2003 11 18
22. N.M. Laird, and J.H. Ware Random-effects models for longitudinal data Biometrics 38 1982 963 974
23. C. Proust-Lima, and J.M. Taylor Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: A joint modeling approach Biostatistics 10 2009 535 549
24. C.A. Bellera, J.A. Hanley, and L. Joseph Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer Ann Epidemiol 18 2008 270 282
25. D.K. Pauler, and D.M. Finkelstein Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes Stat Med 21 2002 3897 3911
26. I.D. Kaplan, R.S. Cox, and M.A. Bagshaw A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy Cancer 68 1991 400 405
27. G.E. Hanks, A. D'Amico, and B.E. Epstein Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time Int J Radiat Oncol Biol Phys 27 1993 125 127
28. J.M. Martin, T. Rosewall, and A. Bayley Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma Int J Radiat Oncol Biol Phys 69 2007 1084 1089
29. I. Aref, L. Eapen, and O. Agboola The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma Radiother Oncol 48 1998 203 207
30. M.E. Ray, H.D. Thames, and L.B. Levy PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis Int J Radiat Oncol Biol Phys 64 2006 1140 1150